July 15, 2016
Authored and Edited by Elizabeth D. Ferrill; Meredith H. Boerschlein*, Jeff T. Watson
In Rapid Litigation Management Ltd. v. CellzDirect, Inc., No. 15-1570 (Fed. Cir. July 5, 2016), the Federal Circuit vacated and remanded the district court’s summary judgment determination that the patent-in-suit is directed to patent-ineligible subject matter and therefore invalid.
Rapid Litigation Management sued CellzDirect for infringing its patent covering a method of preserving hepatocytes (liver cells). CellzDirect moved for summary judgment alleging the patent was invalid under 35 U.S.C. § 101. The district court agreed, applying the two-part test for patent eligibility established in Mayo Collaborative Servs. v. Prometheus Labs., Inc. and confirmed in Alice Corp. v. CLS Bank International. According to the district court, the claims concerned a law of nature (hepatocytes’ ability to survive multiple freeze-thaw cycles), and the well-known freezing method did not provide the requisite “inventive concept.”
On appeal, the Federal Circuit disagreed with the district court’s application of the Mayo/Alice test. Unlike the court below, the Federal Circuit found that the patent did not concern a law of nature, but rather “a new and useful laboratory technique[.]” As the Court further articulated, even if the patent is directed to a law of nature, it is eligible under step two. The twice-frozen process provides an inventive concept.
In reaching its conclusion, the Court added two points: (1) “patent-eligibility does not turn on ease of execution or obviousness of application”; and (2) “while pre-emption is not the test for determining patent-eligibility,” the district court’s findings that the patent “does not lock up the natural law in its entirety” and that “LTC has already managed to engineer around the patent” are in accord with the Court’s conclusion that “the patent is not ‘directed to’ a patent-ineligible building block of human ingenuity.” Thus, the Court vacated and remanded the district court’s summary judgment grant.
*Meredith H. Boerschlein is a Law Clerk at Finnegan.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Webinar
February 15, 2024
Webinar
Webinar
Navigating Your Life Sciences Opposition: Tips for Best Practice When You Are Opposing or Opposed
December 12, 2023
Webinar
Seminar
Protecting Your Life Sciences Innovations: Challenges in the USA and Europe
July 27, 2023
Taipei
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.